BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 15/02/2012

Draft Guidance for Industry on Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product; Availability

The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product." This draft guidance is intended to provide sponsors with an overview of analytical factors to consider when assessing biosimilarity between a proposed protein product and a reference product for the purpose of submitting a marketing application through an abbreviated licensure pathway. This draft guidance provides an overview of FDA's approach to quality considerations in determining biosimilarity.

Source: Federal Register — Food and Drug AdministrationOpen original release →